Squarepoint
PCVX icon

Squarepoint’s Vaxcyte PCVX Stock Holding History

Squarepoint’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,900
Closed -$1.47M – 5208
2024
Q4 		$1.47M Buy
+17,900
New +$1.78M ﹤0.01% 2704

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Squarepoint's PCVX Position: Q3 2026 in Review

Squarepoint opened a new position in Vaxcyte (PCVX) in Q3 2026: 6,822 shares worth $388K. The stake represents ﹤0.01% of the portfolio and ranks #3580 among its holdings. This is a return to the name: Squarepoint previously reported a position in PCVX as recently as Q2 2025.

Squarepoint first reported a position in PCVX in Q4 2020 and has held it in 12 quarters since. The position peaked at $30.8M in Q4 2024. 202 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Squarepoint held 6,822 shares of Vaxcyte worth $388K as of Q3 2026.
  • Vaxcyte was a new Squarepoint position in Q3 2026.
  • Vaxcyte made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3580 holding.
  • Squarepoint first reported a position in Vaxcyte in Q4 2020 and has held it in 12 quarters since.
  • Squarepoint's Vaxcyte position peaked at $30.8M in Q4 2024.
  • 202 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.